Orion Porfolio Solutions LLC Sells 103,908 Shares of Haleon PLC Sponsored ADR $HLN

Orion Porfolio Solutions LLC lowered its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 33.1% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 209,784 shares of the company’s stock after selling 103,908 shares during the period. Orion Porfolio Solutions LLC’s holdings in Haleon were worth $1,882,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. SOA Wealth Advisors LLC. increased its stake in Haleon by 60.5% during the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after acquiring an additional 1,170 shares during the period. Citizens National Bank Trust Department lifted its position in shares of Haleon by 167.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after acquiring an additional 2,051 shares during the period. Atlantic Union Bankshares Corp lifted its position in shares of Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after acquiring an additional 2,758 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. Finally, Mather Group LLC. bought a new stake in shares of Haleon during the third quarter valued at approximately $52,000. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Price Performance

Haleon stock opened at $10.00 on Thursday. The business has a 50 day simple moving average of $10.50 and a 200 day simple moving average of $9.85. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The company has a market capitalization of $44.51 billion, a PE ratio of 25.63 and a beta of 0.18. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

Haleon Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio (DPR) is presently 61.54%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.